What Is CCK-4? Definition and What Research Reports

Definition

CCK-4, short for cholecystokinin tetrapeptide, is a four-amino-acid peptide (Trp-Met-Asp-Phe-NH₂) that corresponds to the C-terminal fragment of cholecystokinin, a hormone produced in the gastrointestinal tract and also expressed widely in the central nervous system. Because this short tail carries the portion of the parent molecule that binds cholecystokinin receptors, CCK-4 retains biological activity despite its small size. In laboratory settings it has been administered intravenously as a research probe rather than as a therapeutic product, and it is best known in psychiatry and neuroscience as an experimental agent that reliably and briefly provokes anxiety and panic-type symptoms in volunteers under monitored conditions. This page is for educational purposes only and is not medical advice; consult a licensed physician for any questions about health, symptoms or medical treatment.

What Class of Molecule It Is and Where the Term Comes From

Cholecystokinin itself is a peptide hormone released from enteroendocrine cells of the small intestine, where it is classically associated with gallbladder contraction, pancreatic enzyme secretion and satiety signalling. The hormone circulates in several lengths — CCK-58, CCK-33, CCK-8 and the tetrapeptide — all sharing the same active C-terminus. CCK-4 is the shortest of these naturally occurring fragments. Its comparative selectivity for the CCK-B (CCK₂) receptor subtype, which is abundant in the brain, is the reason researchers adopted it as a central nervous system probe rather than as a gut-function agent.

The name also collides with an unrelated protein. In developmental and cancer biology, PTK7/CCK-4 refers to protein tyrosine kinase 7, a transmembrane receptor described as a regulator of planar cell polarity in vertebrates (PMID 15229603). Readers encountering "CCK-4" in a genetics or oncology paper are almost always reading about that kinase, not the tetrapeptide. The two share nothing beyond an abbreviation.

How the Term Is Used in Peptide Research

Within human experimental psychiatry, CCK-4 functions as a challenge agent: a substance given deliberately, under supervision, to induce a transient, reversible state so that the state itself can be measured. Investigators have used it to study the neurobiology of panic, to test whether candidate medications blunt the response, and to look for biological markers that track with symptom intensity. Studies of this kind are conducted in controlled clinical-research environments with monitoring, and CCK-4 is not an approved medicine in the United States.

A separate strand of the literature uses cholecystokinin more broadly — not the tetrapeptide specifically — as a satiety signal in animal work. Researchers reported differential feeding behaviour and differing neuronal responses to CCK in obesity-prone versus obesity-resistant rats (PMID 19857467), and a separate rodent study examined the interaction of thyrotropin-releasing hormone and CCK in the satiation of alcohol intake (PMID 15234590). These lines of research explain why the abbreviation sometimes appears in appetite and ingestive-behaviour contexts as well.

What the Published Literature Reports

Panic provocation in healthy volunteers

Human challenge studies form the largest body of CCK-4 literature. One report described psychophysiological conditioning following CCK-4 administration and noted that the elicited episodes displayed features of spontaneous panic attacks (PMID 20451215). Investigators have also examined whether individual differences shape the response: one study reported associations between personality traits and CCK-4-induced panic attacks in healthy volunteers (PMID 20471107).

A study combining CCK-4 with a carbon-dioxide paradigm used 10 µg CCK-4 as premedication before a 35% CO₂ challenge in healthy volunteers (PMID 10836489). That dose figure is reported here only as a description of what the cited study administered; it is not a recommendation, and no other dose appears in the verified literature summarised on this page.

Brain imaging

Functional imaging has been applied to the challenge model. Researchers mapped the functional neuroanatomy of CCK-4-induced panic attacks in healthy volunteers, characterising the brain regions engaged during the induced episodes (PMID 18095276). Work of this type is one reason the model has persisted: it produces a time-locked event that can be captured inside a scanner.

Biomarkers

Several groups have asked whether a blood marker tracks the induced state. One study investigated copeptin as a potential endocrine surrogate marker of CCK-4-induced panic symptoms (PMID 27871026). A later report examined copeptin in CCK-4-induced panic in healthy men and described sexual dimorphisms in both the secretion pattern and the panic response, while finding no correlation between copeptin and panic symptoms (PMID 31525566). Separately, investigators reported that CCK-4-induced anxiety, but not panic, was associated with serum brain-derived neurotrophic factor in healthy subjects (PMID 18562429/).

Pharmacological modulation

Because the challenge produces a measurable endpoint, it has been used to test whether drugs attenuate the response. One trial reported that vigabatrin decreased cholecystokinin-tetrapeptide-induced panic in healthy volunteers (PMID 11682253). Results such as this are typically framed as evidence about mechanism — in that case, GABAergic involvement — rather than as evidence for a clinical treatment.

CCK-4 Effects: What Studies Report

The defining reported effect of intravenous CCK-4 in the human challenge literature is a brief, self-limited episode resembling a panic attack. Investigators described these induced episodes as sharing features with spontaneous panic attacks (PMID 20451215), and the extent of the reaction has been reported to vary with individual personality traits (PMID 20471107) and, in one copeptin study, with sex (PMID 31525566). Because the intent of these studies was to provoke symptoms deliberately in monitored settings, the "effect" and the "adverse event" are, in this model, the same phenomenon. Nothing in this literature describes CCK-4 as a treatment or as a substance with a favourable-experience profile.

Where the Term Appears Outside Psychiatry

Clinicians encounter cholecystokinin in nuclear medicine, where a CCK agent is used to stimulate gallbladder contraction during hepatobiliary scanning. One review concluded that in most cases neither delayed imaging nor CCK administration was needed when bowel excretion did not occur but the gallbladder filled promptly (PMID 31297700). That clinical use involves cholecystokinin analogues acting on the peripheral CCK-A receptor pathway and is conceptually distinct from the CCK-4 panic-challenge literature, even though the abbreviations overlap.

Summary of the Entry

• Molecule class: short peptide; four amino acids; C-terminal fragment of the gut-brain hormone cholecystokinin.
• Primary research use: intravenous panic-provocation probe in supervised human experimental psychiatry.
• Reported findings: induced episodes with features of spontaneous panic (PMID 20451215), mapped brain-activation patterns (PMID 18095276), attenuation by vigabatrin (PMID 11682253), and mixed biomarker results for copeptin (PMID 27871026).
• Naming caution: PTK7/CCK-4 is an unrelated receptor tyrosine kinase in developmental biology (PMID 15229603).
• Status: a research probe, not an approved medicine.

This entry summarises what the cited publications state and does not offer instructions, protocols or recommendations of any kind.

References

• 10 microg CCK-4 premedication and 35% CO2 challenge in healthy volunteers (Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2000)
• Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers (Neuropsychopharmacology, 2001)
• PTK7/CCK-4 is a novel regulator of planar cell polarity in vertebrates (Nature, 2004)
• Interaction of TRH and CCK in the satiation of alcohol intake (Physiology & Behavior, 2004)
• Functional neuroanatomy of CCK-4-induced panic attacks in healthy volunteers (Human Brain Mapping, 2009)
• CCK-4-induced anxiety but not panic is associated with serum brain-derived neurotrophic factor in healthy subjects (Journal of Psychopharmacology, 2009)
• Differential feeding behavior and neuronal responses to CCK in obesity-prone and -resistant rats (Brain Research, 2010)
• CCK-4: Psychophysiological conditioning elicits features of spontaneous panic attacks (Journal of Psychiatric Research, 2010)
• Associations between personality traits and CCK-4-induced panic attacks in healthy volunteers (Psychiatry Research, 2010)
• Copeptin - A potential endocrine surrogate marker of CCK-4-induced panic symptoms? (Psychoneuroendocrinology, 2017)
• No delayed imaging or CCK administration is needed in most cases when bowel excretion does not occur but gallbladder fills promptly (Annals of Nuclear Medicine, 2019)
• Copeptin in CCK-4-induced panic in healthy man: Sexual dimorphisms in secretion pattern and panic response, but no correlation of copeptin with panic symptoms (Psychoneuroendocrinology, 2019)